PIK3CG and melanoma: Since both BRAF/MAPK and PI3K/Akt signaling axes impinge on mTORC1 activity in the presence of sufficient amino acid levels [242] (Figure 3), mTORC1 activation in response to BRAF or MEK inhibition has been monitored in BRAFi sensitive and BRAFi resistant BRAFV600E melanoma cells [298].